T. Black

发表

Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.

Chinyere N. Onyebuchi, W. Greaves, P. McNicholas, 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Mapping and Characterization of Vicriviroc Resistance Mutations From HIV-1 Isolated from Treatment-Experienced Subjects Enrolled in a Phase II Study (VICTOR-E1)

P. Mann, P. McNicholas, J. Strizki, 2011, Journal of acquired immune deficiency syndromes.

Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial.

C. Tremblay, J. Whitcomb, W. Greaves, 2010, The Journal of infectious diseases.

Screening for Antibacterial Inhibitors of the UDP-3-O-(R-3-Hydroxymyristoyl)- N-Acetylglucosamine Deacetylase (LpxC) Using a High-Throughput Mass Spectrometry Assay

F. Monsma, A. Malikzay, D. Daubaras, 2010, Journal of biomolecular screening.

In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts

D. Loebenberg, P. Mann, C. Mendrick, 2006, Antimicrobial Agents and Chemotherapy.

EmtA, a rRNA methyltransferase conferring high‐level evernimicin resistance

F. Aarestrup, A. Mankin, R. Goering, 2001, Molecular microbiology.

Evernimicin (SCH27899) Inhibits a Novel Ribosome Target Site: Analysis of 23S Ribosomal DNA Mutants

D. Loebenberg, K. Klugman, K. Shaw, 2000, Antimicrobial Agents and Chemotherapy.

Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin

A. Sattar, A. Therien, L. Hernandez, 2016, Antimicrobial Agents and Chemotherapy.

Escherichia coli acetyl-coenzyme A carboxylase: characterization and development of a high-throughput assay.

Yan-Hui Liu, A. Soriano, Erik F. Langsdorf, 2006, Analytical biochemistry.

Effects of Mutations in Ribosomal Protein L16 on Susceptibility and Accumulation of Evernimicin

P. Mann, P. McNicholas, R. Hare, 2001, Antimicrobial Agents and Chemotherapy.

HcwA, an Autolysin, Is Required for Heterocyst Maturation in Anabaena sp. Strain PCC 7120

Jinsong Zhu, O. Koksharova, C. Wolk, 2001, Journal of bacteriology.

Design and synthesis of potent Gram-negative specific LpxC inhibitors.

P. Orth, D. Daubaras, P. McNicholas, 2011, Bioorganic & medicinal chemistry letters.

Impact of Antifungal Prophylaxis on Colonization and Azole Susceptibility of Candida Species

P. Mann, C. Mendrick, Reena Patel, 2009, Antimicrobial Agents and Chemotherapy.

Microbial genetics: Genetic strategies for antibacterial drug discovery

J. Greene, Lynn Miesel, Jonathan Greene, 2003, Nature Reviews Genetics.

Crystallization and preliminary X-ray analysis of the acyl carrier protein synthase (AcpS) from Staphylococcus aureus.

P. Orth, D. Daubaras, B. Beyer, 2004, Acta crystallographica. Section D, Biological crystallography.

Temporal Appearance of Plasmid-Mediated Quinolone Resistance Genes

G. Jacoby, D. Hooper, T. Black, 2009, Antimicrobial Agents and Chemotherapy.

Isolation and structure elucidation of Sch 642305, a novel bacterial DNA primase inhibitor produced by Penicillium verrucosum.

A. McPhail, V. Gullo, J. Terracciano, 2003, Journal of natural products.

Two novel antibiotics, Sch 419558 and Sch 419559, produced by Pseudomonas fluorescens: effect on activity by overexpression of RpoE.

Shu-wei Yang, V. Gullo, J. Terracciano, 2004, Bioorganic & medicinal chemistry.

The optimization of pyridazinone series of glucan synthase inhibitors.

R. J. Herr, Jianhua Cao, Jinhai Yang, 2012, Bioorganic & medicinal chemistry letters.

Murgocil is a highly bioactive staphylococcal-specific inhibitor of the peptidoglycan glycosyltransferase enzyme MurG.

P. M. Pereira, F. Monsma, T. Roemer, 2013, ACS chemical biology.

Discovery of wall teichoic acid inhibitors as potential anti-MRSA β-lactam combination agents.

T. Roemer, Timothy C. Meredith, S. Walker, 2013, Chemistry & biology.

A small-molecule inhibitor of BamA impervious to efflux and the outer membrane permeability barrier

T. Roemer, T. Silhavy, Adam G Schwaid, 2019, Proceedings of the National Academy of Sciences.

Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical Candidates

D. Wyss, A. Therien, T. Fischmann, 2022, Journal of Medicinal Chemistry.

Lesions in Teichoic Acid Biosynthesis in Staphylococcus aureus Lead to a Lethal Gain of Function in the Otherwise Dispensable Pathway

Wenjun Zhao, Eric D. Brown, E. Brown, 2006, Journal of bacteriology.

Spatial expression and autoregulation of hetR, a gene involved in the control of heterocyst development in Anabaena

C. Wolk, Y. Cai, C. Peter Wolk, 1993, Molecular microbiology.

Mutations in Ribosomal Protein L16 Conferring Reduced Susceptibility to Evernimicin (SCH27899): Implications for Mechanism of Action

K. Klugman, K. Shaw, R. Hare, 2000, Antimicrobial Agents and Chemotherapy.

Two new bacterial DNA primase inhibitors from the plant Polygonum cuspidatum.

V. Gullo, A. Soriano, Wenjun Zhao, 2004, Bioorganic & medicinal chemistry letters.

Evernimicin Binds Exclusively to the 50S Ribosomal Subunit and Inhibits Translation in Cell-Free Systems Derived from both Gram-Positive and Gram-Negative Bacteria

K. Shaw, P. Mann, P. McNicholas, 2000, Antimicrobial Agents and Chemotherapy.

, David Gram-Positive and Gram-Negative Bacteria in Cell-Free Systems Derived from both Ribosomal Subunit and Inhibits Translation Evernimicin Binds Exclusively to the 50 S

K. Shaw, P. Mann, P. McNicholas, 2000 .

Sphingolipid biosynthesis in pathogenic fungi: identification and characterization of the 3-ketosphinganine reductase activity of Candida albicans and Aspergillus fumigatus.

Li Xiao, S. Walker, K. Koch, 2006, Biochimica et biophysica acta.

Structure of sch 419560, a novel alpha-pyrone antibiotic produced by Pseudomonas fluorescens.

J. Terracciano, T. Black, M. Patel, 2002, The Journal of antibiotics.

Inhibitor of intramembrane protease RseP blocks the σE response causing lethal accumulation of unfolded outer membrane proteins

T. Roemer, T. Silhavy, N. W. Rigel, 2018, Proceedings of the National Academy of Sciences.

Are outer-membrane targets the solution for MDR Gram-negative bacteria?

S. Walker, T. Black, 2021, Drug discovery today.

Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase

T. Roemer, Xinwei Sher, G. Scapin, 2017, PloS one.

Discovery and optimization of antibacterial AccC inhibitors.

Zhiwei Yang, P. Orth, P. Mann, 2009, Bioorganic & medicinal chemistry letters.

Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3).

R. Nargund, Akinori Nishimura, Jin Wu, 2015, Bioorganic & medicinal chemistry letters.

Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2).

Leo A. Joyce, E. Sherer, R. Nargund, 2015, Bioorganic & medicinal chemistry letters.

Structure of Sch 419560, a Novel α-Pyrone Antibiotic Produced by Pseudomonas fluorescens.

Wenjun Zhao, Mahesh Patel, T. Chan, 2002 .

SAR studies of pyridazinone derivatives as novel glucan synthase inhibitors.

R. J. Herr, Jianhua Cao, Jinhai Yang, 2011, Bioorganic & medicinal chemistry letters.

Structure elucidation of Sch 538415, a novel acyl carrier protein synthase inhibitor from a microorganism.

Shu-wei Yang, V. Gullo, Mahesh Patel, 2003, Bioorganic & medicinal chemistry letters.

Lead optimization of a sulfonylurea-based piperazine pyridazinone series of glucan synthase inhibitors.

R. J. Herr, S. Walker, R. Kuang, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a Novel Class of Orally Active Antifungal β-1,3-d-Glucan Synthase Inhibitors

R. J. Herr, P. Mann, S. Walker, 2011, Antimicrobial Agents and Chemotherapy.

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons

D. Hazuda, E. Asante-Appiah, A. Howe, 2016, Antimicrobial Agents and Chemotherapy.

Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection

E. Asante-Appiah, F. Lahser, J. Palcza, 2018, Antiviral therapy.